Canada's Med BioGene Files for IPO in US, Plans Expansion

Med BioGene's flagship offering is LungExpress Dx, a 15-gene-signature test for use in identifying those patients with early-stage non-small-cell lung cancer who are at a higher or lower risk of mortality following surgical removal of their tumor.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories